A 39-amino-acid 'twincretin' that activates both GLP-1 and GIP receptors simultaneously. Achieves up to 22.5% weight loss — the most effective anti-obesity medication ever approved.
Tirzepatide is the first dual GLP-1/GIP receptor agonist — sometimes called a 'twincretin' — approved for clinical use. It simultaneously activates both incretin hormone receptors, producing synergistic effects on blood sugar control and weight loss that exceed what either pathway achieves alone.
Developed by Eli Lilly and marketed as Mounjaro (diabetes) and Zepbound (obesity), tirzepatide achieved unprecedented weight loss in clinical trials. In the SURMOUNT-1 trial, patients on the highest dose lost an average of 22.5% of their body weight — results comparable to bariatric surgery.
Tirzepatide's sequence is based on the native GIP hormone but has been engineered at key positions to also activate the GLP-1 receptor. This cross-reactivity was achieved through specific amino acid substitutions that allow the peptide to bind in both receptor pockets — a remarkable feat of peptide engineering.
Tirzepatide's dual mechanism distinguishes it from pure GLP-1 agonists. The GLP-1 receptor activation provides the same benefits as semaglutide — glucose-dependent insulin, glucagon suppression, delayed gastric emptying, and central appetite suppression. The additional GIP receptor activation adds complementary effects on adipose tissue metabolism and potentially on bone health.
| Pathway | Effect | Significance |
|---|---|---|
| GIP receptor activation | Enhances fat tissue metabolism and energy expenditure | May promote more favorable body composition during weight loss |
| β-cell function | Dual receptor stimulation more effectively restores β-cell glucose sensitivity | Superior glycemic control vs GLP-1 alone |
| Lipid metabolism | Reduces triglycerides and improves cholesterol profile | Cardiovascular risk reduction beyond weight loss |
| Bone metabolism | GIP signaling may protect against bone loss during weight loss | Potential advantage over GLP-1-only agents |
Tirzepatide's clinical trial program is among the most impressive in metabolic disease history.
| Study Area | Design | Key Findings | Evidence |
|---|---|---|---|
| SURMOUNT-1 | Phase III, obesity, n=2,539 | 22.5% mean weight loss at highest dose (15mg); 63% lost ≥20% body weight | Level I |
| SURPASS 1-5 | Phase III, T2D, n=6,000+ | Superior HbA1c reduction vs semaglutide, insulin, and placebo | Level I |
| SURMOUNT-MMO | Phase III, CV outcomes | Ongoing; evaluating MACE reduction in obesity | Pending |
| Sleep apnea | Phase III (Zepbound) | FDA-approved for moderate-severe obstructive sleep apnea in adults with obesity (Dec 2024) | Level I |
GI side effects: Similar profile to GLP-1 agonists: nausea (~25-30%), diarrhea, vomiting. Generally improves with gradual dose titration.
Thyroid warning: Same boxed warning as GLP-1 agonists for thyroid C-cell tumors in rodents. Contraindicated with MTC history.
Pancreatitis risk: Rare acute pancreatitis cases reported. Same monitoring recommendations as GLP-1 class.
Injection site reactions: Mild injection site reactions in ~3-5% of patients.
| Jurisdiction | Status |
|---|---|
| FDA | Approved: Mounjaro (T2D, 2022), Zepbound (obesity, 2023; OSA, 2024) |
| EMA | Approved for T2D and weight management |
| WADA | Not banned |